The DOI matches its Crossref record; 221 of the 222 references it cites were found in a registry or an index.
Current Challenges in Vaccinology
Open accessAbstract
The development of vaccines, which prime the immune system to respond to future infections, has led to global declines in morbidity and mortality from dreadful infectious communicable diseases. However, many pathogens of public health importance are highly complex and/or rapidly evolving, posing unique challenges to vaccine development. Several of these challenges include an incomplete understanding of how immunity develops, host and pathogen genetic variability, and an increased societal skepticism regarding vaccine safety. In particular, new high-dimensional omics technologies, aided by bioinformatics, are driving new vaccine development (vaccinomics). Informed by recent insights into pathogen biology, host genetic diversity, and immunology, the increasing use of genomic approaches is leading to new models and understanding of host immune system responses that may provide solutions in the rapid development of novel vaccine candidates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Despite their evident success, however, conventional vaccines do not effectively tackle pathogens such as the malaria parasite Plasmodium falciparum, hepatitis C and human immunodeficiency virus (HIV), which evade immune surveillance2.”
From mRNA vaccines for infectious diseases: principles, delivery and clinical translation (2021) · cites this paper as [2]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–221 of 221
Comparative Pathogenesis and Systems Biology for Biodefense Virus Vaccine Development
Bowick, G. C., & Barrett, A. D. T. (2010) · BioMed Research International · doi:10.1155/2010/236528 · Cited by 13
Computational Modeling of Hepatitis C Virus Envelope Glycoprotein Structure and Recognition
Guest, J. D., & Pierce, B. G. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01117 · Cited by 13
Revolutionizing Cancer Immunology: The Power of Next-Generation Sequencing Technologies
Singer, M., & Anderson, A. C. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0281 · Cited by 13
Bacterial genetics and molecular pathogenesis in the age of high throughput DNA sequencing
Davey, L. E., & Valdivia, R. H. (2020) · Current Opinion in Microbiology · doi:10.1016/j.mib.2020.01.007 · Cited by 13
Advancing systems immunology through data-driven statistical analysis
Fong, L. E., Muñoz-Rojas, A. R., & Miller‐Jensen, K. (2018) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2018.03.009 · Cited by 12
The potential of metabolic profiling for vaccine development
Weiner, J. M., Mohney, R. P., & Kaufmann, S. H. E. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.07.002 · Cited by 12
Chapman, L. E., Iskander, J. K., Chen, R. T., Neff, J. M., Birkhead, G. S., Poland, G. A., Gray, G. C., Siegel, J. D., Sepkowitz, K. A., Robertson, R. M., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/524750 · Cited by 11
Self-citationHunt, D. F., Henderson, R. A., Shabanowitz, J., Sakaguchi, K., Michel, H., Sevilir, N., Cox, A. L., Appella, E., & Engelhard, V. H. (2007) · PubMed · Cited by 9
McKinney, B. A., Lareau, C. A., Oberg, A. L., Kennedy, R. B., Ovsyannikova, I. G., & Poland, G. A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158016 · Cited by 9
Self-citationSousa, S. A., Seixas, A. M. M., & Leitão, J. H. (2018) · Vaccines · doi:10.3390/vaccines6020034 · Cited by 9
Investigating the aetiology of adverse events following HPV vaccination with systems vaccinology
Campbell-Tofte, J., Vrahatis, A. G., Josefsen, K. E., Mehlsen, J., & Winther, K. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2925-6 · Cited by 9
What can we learn about influenza infection and vaccination from transcriptomics?
Rao, S., Ghosh, D., Asturias, E. J., & Weinberg, A. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1608744 · Cited by 9
Bae, J. (2019) · Journal of Preventive Medicine and Public Health · doi:10.3961/jpmph.19.018 · Cited by 8
Shooting Movies of Signaling Network Dynamics with Multiparametric Cytometry
Claassen, M. (2013) · Current topics in microbiology and immunology · doi:10.1007/82_2013_350 · Cited by 7
A bioinformatics roadmap for the human vaccines project
Scheuermann, R. H., Sinkovits, R. S., Schenkelberg, T., & Koff, W. C. (2017) · Expert Review of Vaccines · doi:10.1080/14760584.2017.1322752 · Cited by 7
The Impact of Nucleotide Sequence Analysis on Meningococcal Vaccine Development and Assessment
Maiden, M. C. J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03151 · Cited by 7
Smallpox Vaccination-associated Myopericarditis is More Common with the Newest Smallpox Vaccine
Bruner, D. I., & Butler, B. S. (2013) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2013.06.001 · Cited by 6
Broad Immune Monitoring and Profiling of T Cell Subsets with Mass Cytometry
Brodie, T. M., & Toševski, V. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7680-5_4 · Cited by 6
How Can Systems Biology Test Principles and Tools Using Immune Cells as a Model?
(2018) · Cell Systems · doi:10.1016/j.cels.2018.02.005 · Cited by 5
What Can Immunologists Learn from Systems Approaches?
Germain, R. N., Greenbaum, B. D., Hoffmann, A., Miller-Jensen, K., Mora, T., Walczak, A. M., Segal, E., Vogl, T., Klompus, S., Peled-Liviatan, S., et al. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.01.002 · Cited by 4
Williamson, E. D., & Oyston, P. C. F. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-0090-5.00031-8 · Cited by 2
Flagged first, then by citations
1 of the 222 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
mRNA vaccines for infectious diseases: principles, delivery and clinical translation
Chaudhary, N., Weissman, D., & Whitehead, K. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00283-5 · Cited by 1,555
mRNA vaccines in disease prevention and treatment
Zhang, G., Tang, T., Chen, Y., Huang, X., & Liang, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01579-1 · Cited by 273
Han, X., Alu, A., Liu, H., Shi, Y., Wei, X., Cai, L., & Wei, Y. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.01.011 · Cited by 165
Knife’s edge: Balancing immunogenicity and reactogenicity in mRNA vaccines
Lee, J., Woodruff, M. C., Kim, E. H., & Nam, J. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-00999-x · Cited by 141
Nanomedicine for COVID-19: the role of nanotechnology in the treatment and diagnosis of COVID-19
Vahedifard, F., & Chakravarthy, K. V. (2021) · Emergent Materials · doi:10.1007/s42247-021-00168-8 · Cited by 129
Metadata
- Authors
- Kennedy, R. B., Ovsyannikova, I. G., Palese, P., & Poland, G. A.
- Affiliations
- Mayo Clinic (US)
- Icahn School of Medicine at Mount Sinai (US)
- Corresponding author
- Kennedy, Richard B.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2020-06-25
- Volume
- 11
- Pages
- 1181-1181
- ISSN
- 1664-3224 (ISSN-L)
- PMC
- PMC7329983
- OpenAlex
- W3033639218
- Cited by
- 113
- References
- 222
- Citations by year
- 2026: 22 · 2025: 24 · 2024: 21 · 2023: 16 · 2022: 12 · 2021: 17 · 2020: 1
- FWCI
- 1.10
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Immunology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institutes of Health (R01AI033144, R01AI121054, R01AI127365, R01AI132348, R01AI138965, R37AI048793, U01AI089859)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Keywords
- vaccine development, vaccinomics, host genetic variation, host immune response, omics technologies, bioinformatics, infectious disease prevention, emerging pathogens
- MeSH terms
- Vaccinology, Animals, Communicable Disease Control, Humans, Vaccines, Computational Biology
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
